|Bid||3.9600 x 1800|
|Ask||3.9700 x 1800|
|Day's Range||3.8800 - 4.0500|
|52 Week Range||2.3100 - 5.0700|
|Beta (5Y Monthly)||1.48|
|PE Ratio (TTM)||12.06|
|Earnings Date||Mar 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.42|
Buying shares in the best businesses can build meaningful wealth for you and your family. And highest quality companies...
Antares Pharma (ATRS) delivered earnings and revenue surprises of -25.00% and 7.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Antares Pharma (NASDAQ:ATRS) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to $0.03, which were in line with the estimate of $0.03. Revenue of $44,133,000 up by 16.63% from the same period last year, which beat the estimate of $40,750,000. Outlook The upcoming fiscal year's revenue expected to be between $175,000,000 and $200,000,000. Conference Call Details Date: Mar 02, 2021 View more earnings on ATRS Time: 08:30 AM ET Webcast URL: https://streaming.webcasts.com/starthere.jsp?ei=1424766&tp_key=38c62cb12a Technicals Company's 52-week high was at $5.07 52-week low: $1.60 Price action over last quarter: Up 57.89% Company Description Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 2, 2021Antares Pharma's Earnings: A Preview© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.